The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: Is complete cytogenetic response the only desirable endpoint?

Clinical Lymphoma, Myeloma and Leukemia

Volumn 11, Issue 5, 2011, Pages 421-426

  Cortes, Jorge ^a   Quintas Cardama, Alfonso ^a   Jabbour, Elias ^a   O'Brien, Susan ^a   Verstovsek, Srdan ^a   Borthakur, Gautam ^a   Ravandi, Farhad ^a   Garcia Manero, Guillermo ^a   Burton, Elizabeth ^a   Shan, Jenny ^a   Kantarjian, Hagop ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Chronic myeloid leukemia; Complete cytogenetic response; Interferon alfa; Tyrosine kinase inhibitor

Indexed keywords

BAFETINIB; BOSUTINIB; DASATINIB; IMATINIB; NILOTINIB; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ADULT; AGED; ARTICLE; CANCER SURGERY; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; COMPLETE CYTOGENETIC RESPONSE; COMPLETE HEMATOLOGIC RESPONSE; CYTOGENETIC RESPONSE; CYTOGENETICS; DRUG HYPERSENSITIVITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HUMAN; MAJOR CLINICAL STUDY; MINOR CYTOGENETIC RESPONSE; PARTIAL CYTOGENETIC RESPONSE; TREATMENT RESPONSE; CHROMOSOME ABERRATION; CHROMOSOME BANDING PATTERN; DRUG EFFECT; FOLLOW UP; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; MORTALITY; MYELOID LEUKEMIA; REMISSION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHROMOSOME ABERRATIONS; CHROMOSOME BANDING; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, CHRONIC-PHASE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; REMISSION INDUCTION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84856140582     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2011.06.009     Document Type: Article

References (18)

1. Kantarjian HM, O'Brien S, Cortes JE, et al. Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer 2003; 97:1033-41. (Pubitemid 36173155)
2. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. NEngl JMed 2003; 348:994-1004. (Pubitemid 36302244)
3. Kantarjian HM, Giles FJ, Bhalla KN, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase following imatinib resistance or intolerance: 24-month follow-up results. Blood2010; 117:1141-5.
4. Shah NP, Kim DW, Kantarjian H, et al. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica 2010; 95:232-40.
5. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010; 362: 2260-70.
6. Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib demonstrates superior efficacy compared with imatinib in patients with newly diagnosed CML-CP: results from the international randomized phase III ENESTnd trial blood. 2009; 114: [Abstract #LBA-1].
7. Talpaz M, Kantarjian HM, McCredie KB, et al. Hematologic remission and cytogenetic improvement induced by recombinant human interferon-A in chronic myelogenous leukemia. NEngl JMed 1986; 314:1065-69. (Pubitemid 16137079)
8. Deininger M, O'Brien S G, Guilhot F, et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 2009; VOL: 114 [Abstract #1126].
9. Cortes JE, Jones D, O'Brien S, et al. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol 2010; 28:398-404.
10. Cortes JE, Jones D, O'Brien S, et al. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol 2010; 28:392-97.
11. Rosti G, Palandri F, Castagnetti F, et al. Nilotinib for the frontline treatment of Ph (+) chronic myeloid leukemia. Blood2009; 114:4933-38.
12. Garg RJ, Kantarjian H, O'Brien S, et al. The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. Blood2009; 114:4361-8.
13. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European Leukemia Net. J Clin Oncol2009; 27:6041-51.
14. Baccarani M, Rosti G, Castagnetti F, et al. Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia- positive chronic myeloid leukemia: a European Leukemia Net Study. Blood2009; 113:4497-4504.
15. Kaplan EL, Maier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1965; 53:457-81.
16. Kantarjian HM, Talpaz M, O'Brien S, et al. Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood2006; 108:1835-40. (Pubitemid 44394991)
17. Roy L, Guilhot J, Krahnke T, et al. Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood 2006; 108:1478-84. (Pubitemid 44316111)
18. Kantarjian H, Giles F, Bhalla K, et al. Update on imatinib-resistant chronic myeloid leukemia patients in chronic phase (CML-CP) on nilotinib therapy at 24 months: clinical response, safety, and long-term outcomes. Blood 2009; 114 [Abstract #1129].